Trials / Unknown
UnknownNCT02052986
An Open-Label Study of Vascazen in Cardiac Rehab Patients With Deficient Blood Omega-3 Fatty Acid Levels
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- New York Hospital Queens · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators aim to test the hypothesis that dietary supplementation with VASCAZEN will correct omega-3 deficiency in cardiac rehab patients and improve biochemical risk factors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | VASCAZEN | All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA |
Timeline
- Primary completion
- 2015-01-01
- First posted
- 2014-02-03
- Last updated
- 2014-02-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02052986. Inclusion in this directory is not an endorsement.